Sep 29, 2023

Novanta Q3 2023 Earnings Report

Novanta reported strong Q3 2023 results with margin, profit, and cash flow at or above expectations, driven by growth in medical end-markets.

Key Takeaways

Novanta's Q3 2023 revenue was $221.5 million, a slight decrease of 0.7% year-over-year. GAAP net income reached $21.2 million, with diluted EPS at $0.59. Adjusted EBITDA stood at $52.2 million, and operating cash flow was $44.6 million.

GAAP revenue was $221.5 million, a 0.7% decrease compared to Q3 2022.

GAAP net income was $21.2 million, compared to $22.5 million in Q3 2022.

Adjusted EBITDA was $52.2 million, compared to $49.4 million in Q3 2022.

Operating cash flow was $44.6 million, compared to $14.8 million in Q3 2022.

Total Revenue
$222M
Previous year: $223M
-0.7%
EPS
$0.85
Previous year: $0.81
+4.9%
Adjusted EBITDA
$52.2M
Previous year: $49.4M
+5.7%
Gross Profit
$102M
Previous year: $98.4M
+3.2%
Cash and Equivalents
$76M
Previous year: $84.6M
-10.2%
Free Cash Flow
$37.9M
Previous year: $11.5M
+229.8%
Total Assets
$1.19B
Previous year: $1.21B
-1.1%

Novanta

Novanta

Novanta Revenue by Segment

Forward Guidance

For Q4 2023, Novanta expects GAAP revenue between $208 million and $212 million, Adjusted EBITDA between $42 million and $45 million, and Adjusted Diluted EPS between $0.59 and $0.66. For the full year 2023, the Company expects GAAP revenue of approximately $878 million to $882 million, Adjusted Gross Profit Margin to be approximately 46.6% to 46.8%, Adjusted EBITDA to be in the range of $193 million to $196 million and Adjusted Diluted EPS to be in the range of $2.98 to $3.05.